“Tepotinib is an option for patients with advanced disease”

(beraking latest news) – Merck today announced that the Italian Medicines Agency has accepted for reimbursement tepotinib, a new drug for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with genetic alterations that cause skipping epithelial mesenchymal transition factor exon 14 (METex14). Fabrizio Bocchetti, director of the Merck Italia Oncology Business Unit explains the importance of this result.